BG104428A - Composition for the treatment of senile dementia of alzheimer type - Google Patents
Composition for the treatment of senile dementia of alzheimer typeInfo
- Publication number
- BG104428A BG104428A BG104428A BG10442800A BG104428A BG 104428 A BG104428 A BG 104428A BG 104428 A BG104428 A BG 104428A BG 10442800 A BG10442800 A BG 10442800A BG 104428 A BG104428 A BG 104428A
- Authority
- BG
- Bulgaria
- Prior art keywords
- alkyl
- alkoxycarbonyl
- mono
- constituent
- halogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The composition is used in the pharmaceutical industry. The invention concerns a pharmaceutical composition containing as active principles: a constituent (a) selected between 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahy dropyridin and a compound in which: Y represents -CH- or -N-; R1 represents hydrogen, a halogen, a hydroxyl, a CF3, a (C3-C4)alkyl or (C1-C4)alkoxy group; R2 represents hydrogen, a halogen, a hydroxyl, a CF3, (C3-C4)alkyl or (C1-C4)alkoxyl group; R3 and R4 represent each hydrogen, or a (C1-C4)alkyl; X represents (a) a (C3-C6)alkyl; a (C3-C6)alkoxyl; a (C3-C7)carboxyalkyl; a (C1-C4)alkoxycarbonyl(C3-C6)alkyl; a (C3-C7)carboxyalkoxyl; or a (C1-C4)alkoxycarbonyl(C3-C6)alkoxyl; (b) a radical selected among a (C3-C7)cycloalkyl, (C3-C7)cycloalkyloxy, (C3-C7)cycloalkylmethyl, (C3-C7)cyclioalkylamino and cyclohexenyl, said radical capable of being substituted by a halogen, hydroxy, (C1-C4)alkoxy, carboxy, (C1-C4)alkoxycarbonyl, amino, mono- or di-(C1-C4)alkylamino or (c) a group selected among phenyl, phenoxy, phenylamino, N-(C1-C3)alkyl-phenyl-amino, phenylmethyl, p phenylcarbonyl, phenylthio, phenyl sulphonyl, phenylsulphinyl and styryl, said group capable of being mono- or polysubstituted on the phenyl group by a halogen, CF3, (C1-C4)alkyl, (C1-C4)alkoxy, cyano, amino, mono- or di-(C1-C4)alkylamino, carboxy, (C1-C4)alkoxycarbonyl, aminocarbonyl, mono- or di -(C1-C4)alkylaminocarbonyl, amino(C1-C4)alkyl, hydroxy(C1-C4)alkyl, or halogeno(C1-C4)alkyl; optionally in the form of its pharmaceutically acceptable salts; and a constituent (b) active in symptomatic treatment of DAT, optionally in the form of one of its pharmaceutically acceptable salts, provided that when constituent (a) is other than 1-(2napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydr opyridin or one of its pharmaceutically acceptable salts, the constituent (b) is an acetylcholinesterase inhibiting agent. 19 claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9714322A FR2771007B1 (en) | 1997-11-14 | 1997-11-14 | COMBINATION OF ACTIVE INGREDIENTS FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER TYPE |
| FR9714324A FR2771006B1 (en) | 1997-11-14 | 1997-11-14 | COMBINATION OF ACTIVE INGREDIENTS FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER TYPE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG104428A true BG104428A (en) | 2001-08-31 |
| BG64819B1 BG64819B1 (en) | 2006-05-31 |
Family
ID=26233932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG104428A BG64819B1 (en) | 1997-11-14 | 2000-05-11 | Combination of tetrahydropyridins and acetylcholinesterase for treating senile dementia of alzheimer type |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1030671A1 (en) |
| JP (1) | JP2001523642A (en) |
| KR (1) | KR100599350B1 (en) |
| CN (1) | CN1243540C (en) |
| AU (1) | AU743228B2 (en) |
| BG (1) | BG64819B1 (en) |
| BR (1) | BR9814035A (en) |
| CA (1) | CA2309966A1 (en) |
| CO (1) | CO4980891A1 (en) |
| DZ (1) | DZ2649A1 (en) |
| EA (1) | EA003255B1 (en) |
| EE (1) | EE04235B1 (en) |
| HU (1) | HUP0100098A3 (en) |
| ID (1) | ID24933A (en) |
| IL (2) | IL136122A0 (en) |
| IS (1) | IS5482A (en) |
| MY (1) | MY120461A (en) |
| NO (1) | NO20002450L (en) |
| NZ (1) | NZ504420A (en) |
| OA (1) | OA11464A (en) |
| PL (1) | PL194597B1 (en) |
| SA (1) | SA98190747B1 (en) |
| SK (1) | SK286040B6 (en) |
| TR (1) | TR200001262T2 (en) |
| TW (1) | TW585766B (en) |
| UY (1) | UY25247A1 (en) |
| WO (1) | WO1999025363A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2685923T3 (en) * | 2002-06-14 | 2018-10-15 | Toyama Chemical Co., Ltd. | Medicinal composition to improve brain function |
| JP2005534710A (en) * | 2002-08-07 | 2005-11-17 | ノバルティス アクチエンゲゼルシャフト | Method for treating dementia based on APOE genotype |
| CN1520818A (en) * | 2003-02-09 | 2004-08-18 | 山东绿叶天然药物研究开发有限公司 | Cholinesterase inhibitor pharmaceutical composition for senile dementia |
| US8481565B2 (en) | 2004-12-27 | 2013-07-09 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
| EP3099296B1 (en) | 2014-01-31 | 2019-01-30 | Cognition Therapeutics, Inc. | Isoindoline derivative, compositions and methods for treating neurodegenerative disease |
| US11214540B2 (en) | 2017-05-15 | 2022-01-04 | Cognition Therapeutics, Inc. | Compositions for treating neurodegenerative diseases |
| KR102224918B1 (en) | 2018-03-20 | 2021-03-09 | (주)인벤티지랩 | Pharmaceutiical composition comprising memantine and donepezil for preventing or treating cognitive impairment-related disease and preparation method thereof |
| WO2019182319A1 (en) * | 2018-03-20 | 2019-09-26 | (주)인벤티지랩 | Method for preparing pharmaceutical composition for preventing or treating cognitive disorder-associated diseases, and pharmaceutical composition for preventing or treating cognitive disorder-associated diseases, prepared by preparation method |
| CN109265391B (en) * | 2018-11-13 | 2021-11-19 | 枣庄学院 | Biphenyl polysubstituted 1,2,5, 6-tetrahydropyridine compound and synthetic method and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2662355B1 (en) * | 1990-05-22 | 1994-11-10 | Sanofi Sa | USE OF 1- [2- (2-NAPHTYL) ETHYL] -4- (3-TRIFLUOROMETHYLPHENYL) -1,2,3,6-TETRAHYDROPYRIDINE FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF BRAIN AND NEURAL DISORDERS. |
| US5453428A (en) * | 1991-02-14 | 1995-09-26 | The Mount Sinai School Of Medicine Of The City Of New York | Method and composition for the treatment of apathy-amotivation syndrome |
| WO1996027380A1 (en) * | 1995-03-06 | 1996-09-12 | Interneuron Pharmaceuticals, Inc. | Reduction of infarct volume using citicoline |
| FR2736053B1 (en) * | 1995-06-28 | 1997-09-19 | Sanofi Sa | NEWS 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES |
-
1998
- 1998-10-26 CO CO98062479A patent/CO4980891A1/en unknown
- 1998-10-28 TW TW087117874A patent/TW585766B/en not_active IP Right Cessation
- 1998-11-09 JP JP2000520796A patent/JP2001523642A/en not_active Withdrawn
- 1998-11-09 CN CNB988130947A patent/CN1243540C/en not_active Expired - Fee Related
- 1998-11-09 TR TR2000/01262T patent/TR200001262T2/en unknown
- 1998-11-09 EE EEP200000290A patent/EE04235B1/en not_active IP Right Cessation
- 1998-11-09 PL PL98340500A patent/PL194597B1/en not_active IP Right Cessation
- 1998-11-09 NZ NZ504420A patent/NZ504420A/en unknown
- 1998-11-09 BR BR9814035-3A patent/BR9814035A/en not_active Application Discontinuation
- 1998-11-09 HU HU0100098A patent/HUP0100098A3/en unknown
- 1998-11-09 IL IL13612298A patent/IL136122A0/en not_active IP Right Cessation
- 1998-11-09 SK SK711-2000A patent/SK286040B6/en unknown
- 1998-11-09 EP EP98954538A patent/EP1030671A1/en not_active Withdrawn
- 1998-11-09 ID IDW20000860A patent/ID24933A/en unknown
- 1998-11-09 KR KR1020007005231A patent/KR100599350B1/en not_active IP Right Cessation
- 1998-11-09 AU AU11609/99A patent/AU743228B2/en not_active Ceased
- 1998-11-09 EA EA200000412A patent/EA003255B1/en not_active IP Right Cessation
- 1998-11-09 WO PCT/FR1998/002384 patent/WO1999025363A1/en not_active Application Discontinuation
- 1998-11-09 CA CA002309966A patent/CA2309966A1/en not_active Abandoned
- 1998-11-11 DZ DZ980259A patent/DZ2649A1/en active
- 1998-11-12 UY UY25247A patent/UY25247A1/en not_active IP Right Cessation
- 1998-11-14 MY MYPI98005180A patent/MY120461A/en unknown
- 1998-11-14 SA SA98190747A patent/SA98190747B1/en unknown
-
2000
- 2000-05-09 IS IS5482A patent/IS5482A/en unknown
- 2000-05-11 NO NO20002450A patent/NO20002450L/en unknown
- 2000-05-11 BG BG104428A patent/BG64819B1/en unknown
- 2000-05-12 OA OA1200000141A patent/OA11464A/en unknown
- 2000-05-14 IL IL136122A patent/IL136122A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG104428A (en) | Composition for the treatment of senile dementia of alzheimer type | |
| CA2225746A1 (en) | 4-aryl-1-phenylalkyl-1,2,3,6-tetrahydropyridines having neurotrophic and neuroprotective activity | |
| HU910706D0 (en) | Process for producing new n-(4-piperidinyl)-(dihydro-benzofurane- or dihydro-2h-benzopyrane)-carboxamide derivatives and pharmaceutical preparatives containing said compounds | |
| AU2003278296A1 (en) | Piperidine quinolyl propyl derivatives, preparation method and intermediates and compositions containing same | |
| HK1097474A1 (en) | Carbostyril derivatives for accelerating salivation | |
| CA2288241A1 (en) | Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination | |
| GR3032715T3 (en) | New imidazoline derivatives having affinity for the imidazoline receptor | |
| JP2001523642A5 (en) | ||
| ZA9510693B (en) | Use of 5-acyl-1 4-dihydropyridines | |
| RS20060624A (en) | Antimycobacterial pharmaceutical composition | |
| NZ336033A (en) | 4-substituted 1-phenylalkyl-1,2,3,6-tetrahydropyridines for treating alzheimer's disease | |
| CA2242494A1 (en) | Novel n-substituted 4-((4'-aminobenzoyl)-oxymethyl)-piperidines having gastric prokinetic properties | |
| HUP0001181A2 (en) | Micro-particulate form of a tetrahydropyridin derivative and pharmaceutical compositions containing them | |
| RU2003123119A (en) | SODIUM CHANNEL MODULATORS 2-PIPERIDYLIMIDAZOLE DERIVATIVES | |
| BR0209443A (en) | Use of 3- [1- [2- (1-acetyl-2,3-dihydro-1h-indol-3-yl) ethyl] -1,2,3,6-tetrahydropyridin-4-yl ] -6-chloro-1h-indole, any of its enantiomers and pharmaceutically acceptable salts thereof, and method for treating attention-deficit hyperactivity disorder | |
| AR013750A1 (en) | ASSOCIATION OF ACTIVE PRINCIPLES FOR THE TREATMENT OF SENILE DEMENTIA OF ALZHEIMER TYPE | |
| MX9803271A (en) | Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-t etrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis. | |
| MY117156A (en) | Pharmaceutical composition for oral administration | |
| HUP9802896A2 (en) | Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient |